PathAI and the Cleveland Clinic are partnering to identify diseases and provide treatment

PathAI and the Cleveland Clinic are partnering to identify diseases and provide treatment ...

Traditionally, patients undergo a biopsy, their sample tissues or cells have been sent to a pathology laboratory, placed on blocks, divided into sections, stained with tint, and then examined under a microscope.

Even in this era of digitization, that process remains relatively unchanged.

Pathology still lives on glass, according to Brian Rubin, the chair of the Cleveland Clinic''s Pathology and Laboratory Medicine Institute.

Pathologists with microscopes and glass slides are one of the most surprising things about medicine today, according to Dr. Andy Beck, the CEO of PathAI, which is based on AI platform developers. People are surprised that it isn''t digital.

PathAI and Cleveland Clinic are attempting to improve this, as the Northeastern Ohio medical system and the Boston-based developer of AI and deep learning medical pathology tools have embarked on a five-year research collaboration. This partnership will involve digitizing pathology specimens and linking clinical data with digital pathology data. PathAI will also develop algorithms based on analysis of workflows and pathology use in the lab.

Using AI for a cure

The aim of this study is to assist Cleveland Clinic in identifying diseases more quickly and in achieving patients to the best treatment suitable for their needs.

According to Zapat Singh, there is enormous possibility for the formation of new AI-powered pathology algorithms that will be beneficial for research and patient care.

Deep convolutional neural networks (CNNs) are used in PathAIs tools, which include millions of layers of tightly interconnected processing nodes. Using parameters in the tens of millions, these complex networks may identify patterns in images and video.

This program will be implemented at Cleveland Clinic as it prepares to scan 1.5 million slides over five years. The medical system has one of the world''s largest glass databases, according to Rubin, and is able to provide a large range of well-diagnosed slides. As a result, the operator of ten medical facilities in northeastern Ohio has been using digital slide technology on a limited basis for years.

The clinic will purchase several new scanners as part of the project, and a combined a dozen specialists, including analysts, to develop methods to transfer de-identified data to its team of 100 sub-specialized pathologists.

The partnership is really to instill work at an all-time high, which we couldn''t complete on our own, according to Rubin.

Our goal is to provide the best possible treatment for our patients, and it is increasingly evident that artificial intelligence capabilities may radically improve diagnostic accuracy and treatment selection, according to the author. By doing this work, we were able to increase the value of machine learning for our patients and lead to further advancement that will result in better outcomes.

According to Beck, a deeper molecular testing may help obtain more accurate diagnoses.

According to a researcher, deep learning-powered pathology can really broaden research as well as clinical care.

Enhanced diagnosis at scale

Beck and Rubin agreed that widespread digitization has been limited. The biggest challenge, however, is increased debt. Pathology is a low-margin business, and scanning costs vary in the amount of $500,000, as well as upfront software and people costs. At least the benefits the perceived ones have outweighed.

Most people will not try to embark on that at an all-time high, regardless of whether you look at something under a microscope or on a desktop. Rubin said that if there is no extra benefit and its cost-effectiveness, it is unlikely that he or she will have an incentive.

The possibility of data sharing and the capacity to communicate images is immense in the Cleveland Clinic. Physical slides are enormous, and the vast physical space they require might be reduced with digital slides.

More accurate prediction, improved patient outcomes, improved insights into the molecular implications of disease, and insights for research and education are among the broad-reaching implications, according to Rubin.

According to Rubin, pathologists are aware of errors or disappointments, which is why patients are often told to get a second opinion. It''s nice to have a limited safety layer and add additional enhancements of quality, he said.

Precision pathology

PathAI has gained some ground in its niche over six years: In 2021, the company completed a $165 million series C round, and recently acquired Poplar Healthcare Management, one of the country''s largest pathology labs.

According to Beck, PathAI is investing its systems in clinical trials with several healthcare providers and also developing new types of tests that are entirely based on digital images.

The Cleveland Clinic partnership promises many new and diverse opportunities.

Pathology requires robust cataloging, annotation, and retrieval, according to Rubin. Diameters are pulled out of physical archives every time when a patient has a recurrence of cancer, for example, old and new slides are compared. Samples must also be securely stored for varying periods of time based on different regulations.

What are the prerequisite steps to accomplish all of this in the digital world, according to Rubin?

According to the entrepreneur, the partnership aims to address such questions while also establishing algorithms and methods for diagnostics and workflows to bring pathology to a new level.

Rubin said it''s all really new territory. It''s exciting for us, as academic pathologists, to now be working with AI/ML developers.

Beck believes that only about 5% of labs have gone completely digital. However, he believes that the field will be transformed over the next five to 10 years, and that Labs will look quite different.

It will be difficult to get there through partnerships, which require significant time and monetary commitment for providers and tech companies. Beck believes that to break tradition requires a good reason and an motivator and medical institutions need help to recognize the value of improved quality and reproducibility. Those in the tech sector also must assist healthcare stand up and make them less difficult.

With just digitization alone, the benefit hasn''t been enough to switch from glass slides and microscopes, according to Beck. However, once you layer on AI, the value that these digital images can bring is enormous.

Beck claims that we have a great opportunity to accelerate innovation in precision pathology and to use our expertise to bridge organizations in the healthcare arena, including patients, biopharma, and academic research.

You may also like: